Abatacept

CLINICAL USE

Treatment of moderate to severe rheumatoid arthritis in people who have not responded adequately to other treatment

DOSE IN NORMAL RENAL FUNCTION

<60 kg: 500 mg, 60–100 kg: 750 mg, >100 kg: 1000 mgevery 4 weeks after loading

PHARMACOKINETICS

Molecular weight :92 000

%Protein binding :No data

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :0.07

half-life – normal/ESRD (hrs) :13.1 days/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function. Use with caution

<10 : Dose as in normal renal function. Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD :Unlikely to be dialysed. Dose as in GFR<<10 mL/min

HDF/high flux :Unlikely to be dialysed. Dose as in GFR <10 mL/min

CAV/VVHD :Unlikely to be dialysed. Dose as in GFR10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsVaccines: avoid concomitant use with live vaccines

ADMINISTRATION

Reconstition

With 10 mL of water for injection per vial

Route

IV infusion

Rate of Administration

Over 30 minutes

Comments

DO NOT SHAKE when reconstituting Add dose to 100 mL of sodium chloride 0.9%

OTHER INFORMATION

Stable for 24 hours at 2–8°C if made under aseptic conditionsAdminister with an infusion set with a low protein binding filter (pore size 0.2–1.2 μm)Manufacturer does not have any information on its use in renal impairment. Main side effects are infections and malignancies, to which renal patients may be at increased risk, therefore use with caution

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home